Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Clinical and regulatory support services

SectorREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Clinical and regulatory support services

Services that help medtech, diagnostics, digital-health and life-science vendors obtain market access and demonstrate safety, effectiveness and quality. Includes regulatory consulting and submissions, clinical trials and evidence generation, quality and compliance support, health-economic and reimbursement advice, and market-access services. Excludes physical products, software licences and device installation or maintenance.

Market size
$8.5B
$8.5B ($5.5B–$11.2B) · 2025 · Triangulated
Growth
+8.0%
$17.9B by 2034
Attractiveness
75 /100
for B2B sellers
Evidence
Medium confidence
8 sources · Triangulated
Level
Sector
Segmented by
Product or service
Buyers
Medical-device, diagnostic, software and life-science vendors
Value chain
Enabler
Maturity
Growth
Structure
Fragmented
Buying triggers
  • EU MDR transition deadlines and IVDR obligations for diagnostics manufacturers
  • US FDA submission volume growth and new review pathways
  • New product launches requiring simultaneous multi-country registration
  • Payer coverage decisions requiring health-economic dossiers
  • Audit findings and compliance remediation events [4]
Pains
  • Incomplete or inaccurate regulatory data causing audit findings and shipment holds [4]
  • Siloed, manual submission preparation consuming scarce regulatory staff time [4]
  • Fragmented evidence packages slowing approvals and coverage decisions
  • Multi-jurisdiction rule divergence creating rework and schedule risk
Scores (1–5)
Pain intensity4
Purchasing power3
Reachability4
Growth4
Growth drivers
  • Escalating regulatory complexity across EU MDR/IVDR, US FDA and multi-jurisdiction submissions raises in-house workload [2][4]
  • Medtech and diagnostics pipelines need evidence generation to support both approval and payer coverage [1][2]
  • Cost reduction and focus-on-core outsourcing of non-differentiated regulatory and clinical tasks [5][10]
  • Post-market surveillance, vigilance and lifecycle compliance burden grows with installed product base [5]
Headwinds
  • Medtech funding and capital constraints in 2024-2026 slowing vendor spend and project starts
  • In-house capability build-out at larger medtech firms insourcing regulatory affairs [4]
  • Long sales cycles and procurement scrutiny at large device manufacturers
  • Fragmented, low-value commoditised writing and submission-prep work facing price pressure
Trends
  • Shift from document-centric to data-centric regulatory operations and digital quality management [4]
  • Consolidation of niche consultancies into scaled regulatory/quality service platforms
  • Growth of AI-assisted regulatory documentation and dossier automation
  • Expansion of post-market and lifecycle services as a recurring revenue pool [5]

Submarkets 4

Split by product or service.

Submarket75/100

Clinical evidence and trial services

Clinical-trial design, patient and site management, monitoring, data management and evidence-generation services supporting regulatory submissions and payer coverage.

$3.2B
Medical-device, diagnostic and digital-health vendors, pharmaceutical and biotechnology companies
Medium confidenceOpen
Submarket75/100

Regulatory affairs and submissions services

Advice, documentation, testing and submission support for regulatory approval and market authorisation across jurisdictions, including quality-system and technical-file preparation

$3.2B
Medical-device, diagnostic, digital-health and life-science vendors
Medium confidenceOpen
Submarket70/100

Quality, compliance and lifecycle regulatory services

Quality-system implementation, compliance audits, post-market surveillance, vigilance, risk-management and product-lifecycle regulatory support.

$1.2B
Medical-device, diagnostic and digital-health vendors, pharmaceutical and biotechnology companies
Low confidenceOpen
Submarket60/100

Market access, reimbursement and health-economic services

Health-economic assessments, reimbursement dossiers, pricing analysis, payer-engagement strategy and commercial launch support for technologies.

$900M
Medical-device, diagnostic and digital-health vendors, pharmaceutical and biotechnology companies
Low confidenceOpen

How this was sized

$8.5B ($5.5B–$11.2B) · 2025 · Triangulated

Sector defined as clinical and regulatory support services for medtech, diagnostics, digital-health and life-science vendors. Published healthcare regulatory affairs outsourcing estimates cluster at USD 7.5B (2024) rising to USD 8.1B (2025) [9], USD 8.20B (2025) [6], USD 8.40B (2025) [5], USD 8.95B (2025) and USD 9.67B (2026) [10], USD 9.37B (2026) [3], USD 11.20B (2025) [7], and USD 5.5B (2025) [8]. These are pharma-plus-device and include legal representation and writing/publishing, so they overstate the medtech/diagnostics-focused scope; the medtech-specific device regulatory affairs outsourcing line is USD 2.1B (2024) [2]. Sector midpoint taken at USD 8.5B for 2025 with a USD 5.5-11.2B range; forecast anchored on USD 17.9B by 2034 [10] and USD 18.6B by 2034 [5].

Alongside it in Healthtech & medtech

// Sell into Clinical and regulatory support services

AOS finds the biggest accounts in this sector with a reason to talk now, maps their buying centre and prepares the outreach for your approval.